Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Docosahexaenoic Acid (DHA) Supplementation in High Risk Pregnancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04069195
Recruitment Status : Recruiting
First Posted : August 26, 2019
Last Update Posted : August 26, 2019
Sponsor:
Collaborators:
National Institutes of Health (NIH)
DSM Nutritional Products, Inc.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information provided by (Responsible Party):
Walter Reed National Military Medical Center

Brief Summary:

Purpose: Determine the effects of maternal docosahexaenoic acid (DHA) supplementation during pregnancy on levels of DHA, synaptamide (novel anti-inflammatory metabolite), and inflammatory biomarkers during pregnancy and at delivery

Research Design: Double blind randomized placebo-controlled study of maternal DHA supplementation during pregnancy.

Methodology /Technical Approach: Investigators plan to enroll 100 pregnant women with a high risk pregnancy related to (1) a pre-pregnancy Body Mass Index (BMI) of ≥30.0 kg/m2 and/or (2) a history of prior preterm delivery at ≤35+6 weeks gestation. Women will be enrolled between the 8th and 14th week of pregnancy and randomized to receive a once daily DHA supplement (DSM Nutritional Products, Columbia Maryland, DHA capsule 441mg/cap) or a placebo (DSM Nutritional Products, Columbia Maryland, Corn Oil/Soybean oil 50/50 mix) for the duration of the pregnancy. DHA is an omega-3 long chain polyunsaturated fatty acid (LCPUFA) and placebo composed of omega-6 LCPUFA's. Investigators will measure maternal levels of plasma DHA, Synaptamide and inflammatory biomarkers at enrollment, at 26-30 weeks of pregnancy, and from cord blood at delivery. Sociodemographic and clinical characteristics will be collected for each mother from pregnancy onset until discharge following delivery. The infant health record and parental report will be reviewed to record clinical data from birth to 12 months corrected age for short term health outcomes potentially related to inflammation-related morbidities, including growth and development, acute infection requiring hospital admission, and any allergic disorder. All plasma samples will be processed at Dr. Kim's NIAAA/NIH laboratories using high-performance liquid chromatography with tandem mass spectrometry


Condition or disease Intervention/treatment Phase
Inflammation Pregnancy Related Dietary Supplement: DHA supplement Dietary Supplement: Corn Oil: Soybean Oil Not Applicable

Detailed Description:

All pregnant women meeting the inclusion/exclusion criteria will be identified at the time of their regular OB appointments between the 8th and the 14th week of pregnancy (+/- 3 days) Research team members will approach potential subjects to explain the study and obtain consent for their participation Patients who give their consent for enrollment will be asked to complete a dietary survey at the time of enrollment Patients will be given a paper script for study drug to be taken to the Walter Reed Military Medical Center pharmacy to obtain study drug The Investigational Pharmacy will randomize the patients in double blinded fashion to the intervention group or placebo group.

Patients in the intervention group will recieve a ~1000mg capsule containing ~400mg of DHA. This is not standard of care and is being done for research purposes only Patients in the Placebo group will recieve a ~1000mg capusle containing no DHA and filled with 50:50 mix of corn and soybean oils. This oil is ubiquitous in the american diet and only a very small amount of additional oil will be ingested for study purposes. Giving pregnant women this oil is not standard of care and is being done for research purposes only The placebo and intervention drugs will be packaged in the same capsule membrane and will be indistinguishable by color, shape, or taste.

Patients will be instructed to take 1 capule PO daily until their child is delivered Patients will be issued a 3 month supply of study drug at enrollment and will get refills from the investigational pharmacy

≤5ml of whole blood will be obtained from each subject at enrollment and at 26-30 weeks gestation (+/- 3 days), as part of a routine blood sampling. It is standard of care to collect blood at this point in pregnancy for lab evaluation. The additional tube of blood collected for this study is for research purposes only and not part of the standard of care. This sample will be centrifuged, and the separated plasma will be labeled and frozen at -80° C pending transport to Dr. Kim's lab at the National Institute on Alcohol Abuse and Alcoholism (NIAAA) for bulk analyses.

At delivery, ≤5ml of umbilical cord blood will be obtained from an umbilical artery and from the umbilical vein. These samples will be processed and stored in a similar fashion as the earlier samples. Cord blood is a medical waste product, and collection will therefore have no adverse effect for either mother or newborn. It is standard of care to collect cord blood by OB request for lab evaluation. Collecting additional cord blood for this study anaylsis is for research purposes only All enrollees will complete a dietary survey upon enrollment at 8-14 weeks (+/- 3 days), at 26-30th week of pregnancy (+/- 3 days), and during the delivery admission. This survey will also include the subject's self-report on compliance with taking the study supplement All plasma samples collected will be processed at Dr. Kim's National Institute on Alcohol Abuse and Alcoholism/ National Insititute of Health (NIAAA/NIH) laboratories The Cytokine Assays for IL-6, Il-10, TNF- alpha will be run in Dr Kim's lab using Ensyme Linked Immunosorbent Assay (ELISA) testing The DHA and Synaptamide levels will be analyzed in Dr. Kim's lab using High performance liquid chromatrography with tandem mass spectrometry All babies from multiple birth pregnancies will be enrolled in this study The offspring of enrolled women will be followed through 12 months corrected age to assess the longer term outcomes of study intervention Information will be collected from the maternal medical record at time of enrollment, infant delivery and postpartum discharge.

Information will be collected from the infant medical record at time of birth discharge, and 12 months corrected age.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 210 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Double Blinded, Randomized, Placebo controlled
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double blinded, randomized, placebo controlled
Primary Purpose: Prevention
Official Title: Placebo Controlled Trial of Docosahexaenoic Acid (DHA) Supplementation in High Risk Pregnancies
Actual Study Start Date : February 1, 2019
Estimated Primary Completion Date : December 1, 2020
Estimated Study Completion Date : December 1, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: DHA supplement
Patients in the intervention group will recieve a ~1000mg capsule containing ~400mg of DHA. This is not standard of care and is being done for research purposes only. Patients will take this capsule once daily begining between 8-14 weeks of pregnancy until delivery of their infant.
Dietary Supplement: DHA supplement
Patient's will be randomized to recieve either DHA or 50:50 corn oil/soybean oil supplement as a once daily supplement to be taken from enrollment through delivery of their infant
Other Name: Docosahexaenoic Acid

Placebo Comparator: corn oil: Soybean oil placebo
Patients in the Placebo group will recieve a ~1000mg capusle containing no DHA and filled with 50:50 mix of corn and soybean oils. This oil is ubiquitous in the american diet and only a very small amount of additional oil will be ingested for study purposes. Giving pregnant women this oil is not standard of care and is being done for research purposes only. Patients will continue taking this placebo from enrollment at 8-14 weeks of pregnancy until time of delivery.
Dietary Supplement: Corn Oil: Soybean Oil
Patient's will be randomized to recieve either DHA or 50:50 corn oil/soybean oil supplement as a once daily supplement to be taken from enrollment through




Primary Outcome Measures :
  1. Measure DHA [ Time Frame: Sample obtained between 8-14 weeks of pregnancy ]
    Measurement of maternal plasma DHA using tandem mass spec

  2. Measure DHA [ Time Frame: Sample obtained between 26-30 weeks of pregnancy ]
    Measurement of maternal plasma DHA using tandem mass spec

  3. Measure DHA [ Time Frame: Sample obtained from cord blood at time of infant delivery ]
    Measurement of fetal plasma DHA using tandem mass spec

  4. Measure synaptamide [ Time Frame: Sample obtained between 8-14 weeks of pregnancy ]
    Measurement of maternal plasma synaptamide using tandem mass spec

  5. Measure synaptamide [ Time Frame: Sample obtained between 26-30 weeks of pregnancy ]
    Measurement of maternal plasma synaptamide using tandem mass spec

  6. Measure synaptamide [ Time Frame: Sample obtained from cord blood at time of infant delivery ]
    Measurement of fetal plasma synaptamide using tandem mass spec

  7. Measure inflammatory biomarkers [ Time Frame: Sample obtained between 8-14 weeks of pregnancy ]
    Measurement of plasma cytokine levels using ELISA human cytokine panel

  8. Measure inflammatory biomarkers [ Time Frame: Sample obtained between 26-30 weeks of pregnancy ]
    Measurement of plasma cytokine levels using ELISA human cytokine panel

  9. Measure inflammatory biomarkers [ Time Frame: Sample obtained from cord blood at time of infant delivery ]
    Measurement of plasma cytokine levels using ELISA human cytokine panel


Secondary Outcome Measures :
  1. Maternal Gestational weight gain at end of pregnancy in placebo vs. DHA supplement groups [ Time Frame: At time of infant delivery ]
    Compare maternal gestational weight gain at the end of pregnancy between intervention and placebo groups

  2. Infant delivery method [ Time Frame: At time of infant delivery ]
    Compare delivery method used to delivery infant between intervention and placebo groups

  3. Delivery complications [ Time Frame: at time of infant delivery ]
    Compare any documented delivery complications between intervention and placebo groups

  4. Maternal death [ Time Frame: From enrollment in study at 8-14 weeks of pregnancy until 6 months after infant delivery ]
    Number of maternal deaths in intervention group vs placebo group

  5. Pre-eclampsia [ Time Frame: From enrollment in study at 8-14 weeks of pregnancy until 42 weeks of pregnancy or day of infant delivery, whichever happens first ]
    Presence or absence of pre-eclampsia in intervention vs placebo groups

  6. chorioamionitis [ Time Frame: From enrollment in study at 8-14 weeks of pregnancy until 42 weeks of pregnancy or day of infant delivery, whichever happens first ]
    Presence or absence of chorioamionitis in intervention vs placebo groups

  7. Gestational Diabetes Melitus [ Time Frame: From enrollment in study at 8-14 weeks of pregnancy until 42 weeks of pregnancy or day of infant delivery, whichever happens first ]
    Presence or absence of Gestational Diabetes Mellitus in intervention vs placebo groups

  8. non-gestational Diabetes mellitus [ Time Frame: From enrollment in study at 8-14 weeks of pregnancy until 42 weeks of pregnancy or day of infant delivery, whichever happens first ]
    Presence or absence of non-Gestational Diabetes Mellitus in intervention vs placebo groups

  9. Preterm Premature Rupture of Membranes [ Time Frame: From enrollment in study at 8-14 weeks of pregnancy until 42 weeks of pregnancy or day of infant delivery, whichever happens first ]
    Presence or absence of Preterm Premature Rupture of Membranes in intervention vs placebo groups

  10. going past due dates [ Time Frame: during last month of pregnancy ]
    Presence or absence of going past due dates in intervention vs placebo groups

  11. Placental pathology [ Time Frame: at time of delivery ]
    Any placental pathology documented on maternal delivery summary in intervention vs. placebo groups

  12. Head circumference at birth [ Time Frame: At time of infant birth ]
    Measurement of head circumference at birth in placebo vs. Intervention

  13. Length at birth [ Time Frame: At time of infant birth ]
    Measurement of length at birth in placebo vs. Intervention

  14. weight at birth [ Time Frame: At time of infant birth ]
    Measurement of weight at birth in placebo vs. Intervention

  15. Gestational age at birth [ Time Frame: At time of infant birth ]
    Gestational age at infant birth in both placebo and intervention groups

  16. APGAR score at 1 min [ Time Frame: At time of infant birth ]
    APGAR score assessed for infants in both placebo and intervention groups

  17. APGAR score at 5 min [ Time Frame: At time of infant birth ]
    APGAR score assessed for infants in both placebo and intervention groups

  18. Resuscitation beyond warm/dry stimulate at birth [ Time Frame: At time of infant birth ]
    Presence or absence of any resuscitation beyond warm, dry and stimulate at infant birth

  19. Presence or absence or requirement for respiratory assistance within the first 24 hours after birth [ Time Frame: From NICU admission to 24 hours after birth ]
    Presence or absence of any respiratory support outside of the delivery room in first 24 hours of birth placebo vs intervention groups

  20. Days of antibiotic exposure during birth hospitalization [ Time Frame: During birth admission up to 8 months of chronologic age or discharge from hospital whichever happens sooner ]
    Number of 24hr periods in which infant was exposed to antibiotics during birth hospitalization

  21. NICU admission [ Time Frame: Within the first 5 days of infant's life ]
    Presence or absence of NICU admission in placebo vs intervention groups

  22. Duration of birth admission [ Time Frame: Birth through 12 months of age or infant discharge, whichever occurs sooner ]
    Number of 24hr periods patient was present in hospital during birth admission

  23. Requirement for phototherapy during birth admission [ Time Frame: Birth through 14 days of infant life ]
    Presence or absence of phototherapy during birth admission in placebo vs intervention groups

  24. Culture proven sepsis [ Time Frame: From birth through 12 months or until infant discharge whichever occurs sooner ]
    Presence or absence of culture proven sepsis during birth admission in placebo vs intervention groups

  25. Infant Death [ Time Frame: From birth through 12 months or until infant discharge whichever occurs sooner ]
    Number of infants that died during birth hospitalization in both the placebo and intervention groups

  26. Weight at infant hospital discharge [ Time Frame: At time of infant's first discharge from hospital or at 12 months corrected, whichever comes first ]
    Weight at infant hospital discharge in placebo vs intervention group

  27. head circumference at infant hospital discharge [ Time Frame: At time of infant's first discharge from hospital or at 12 months corrected, whichever comes first ]
    head circumference at infant hospital discharge in placebo vs intervention group

  28. Length at infant hospital discharge [ Time Frame: At time of infant's first discharge from hospital or at 12 months corrected, whichever comes first ]
    Length at infant hospital discharge in placebo vs intervention group

  29. Feeding plan at infant discharge [ Time Frame: At 12 months chronological if still admitted or at infant discharge, whichever occurs sooner ]
    Feeding plan documented as exclusive breastfeeding, formula and breastfeeding or exclusive formula feeding

  30. Infant diagnosis in medical record [ Time Frame: at 12 months corrected ]
    Compare infant diagnosis recorded in medical record in placebo vs intervention group

  31. infant weight at 6 months corrected age [ Time Frame: at 6 months corrected ]
    Weight at 6 months corrected age documented in medical record in placebo vs intervention group

  32. infant weight at 12 months corrected age [ Time Frame: at 12 months corrected ]
    Weight at 12 months corrected age documented in medical record in placebo vs intervention group

  33. head circumferene weight at 6 months corrected age [ Time Frame: at 6 months corrected ]
    head circumferene at 6 months corrected age documented in medical record in placebo vs intervention group

  34. head circumference weight at 12 months corrected age [ Time Frame: at 12 months corrected ]
    head circumference at 12 months corrected age documented in medical record in placebo vs intervention group

  35. Length weight at 6 months corrected age [ Time Frame: at 6 months corrected ]
    Length at 6 months corrected age documented in medical record in placebo vs intervention group

  36. Length weight at 12 months corrected age [ Time Frame: at 12 months corrected ]
    Length at 12 months corrected age documented in medical record in placebo vs intervention group

  37. Number of outpatient visits for infant during first 12 months corrected [ Time Frame: birth through12 months corrected ]
    Number of outpatient visits recorded during first 12 months corrected in placebo vs. intervention groups

  38. Failure to thrive in for infant [ Time Frame: birth through 12 months corrected ]
    Presence or absence of diagnosis "failure to thrive" in medical record through first 12 months corrected in placebo vs intervention

  39. number of inpatient days for infant through 12 months corrected [ Time Frame: birth through 12 months corrected ]
    number of inpatient days for infant through 12 months corrected in intervention vs placebo

  40. Indication of infant developmental delay in medical record from birth through 12 months corrected [ Time Frame: birth through 12 months corrected ]
    Presence or absence of any indication of developmental delay recorded by physician in the medical record through 12 months corrected in intervention vs placebo groups

  41. Number of antibiotic prescriptions for infant through first 12 months corrected [ Time Frame: birth through 12 months corrected ]
    Number of antibiotic prescriptions for infant through first 12 months corrected in intervention vs placebo

  42. Documented infant feeding plan through first year [ Time Frame: birth through 12 months corrected ]
    Documented infant feeding plan through first year. Exclusive breastfeeding, formula and breastfeeding or exclusive formula



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Enrolling only pregnant women and their offspring
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • regnant female military health care beneficiaries ≥18 years of age
  • Between the 8th and 14th week of pregnancy at enrollment
  • BMI of ≥30.0 kg/m2 and/or history of previous preterm delivery at <36 weeks gestation
  • Planning to deliver at WRNMMC
  • DEERS-eligible
  • All infants born to mothers enrolled in this study who do not meet any exclusion criteria

Exclusion Criteria:

  • Routine use of DHA supplement (including DHA containing prenatal vitamins) and/or fish consumption greater than twice per week
  • Women with a fish allergy
  • Known major fetal anomaly believed to be lethal
  • Maternal treatment for clotting disorder
  • Allergy to corn or soybean oils

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04069195


Contacts
Layout table for location contacts
Contact: Peter F Knickerbocker, DO 215-298-2476 peteknickerbocker@gmail.com
Contact: Carl Hunt, MD 3017675514 carl.hunt@usuhs.edu

Locations
Layout table for location information
United States, Maryland
Walter Reed National Miltiary medical center Recruiting
Bethesda, Maryland, United States, 20889
Contact: Peter F Knickerbocker, DO    215-298-2476    peteknickerbocker@gmail.com   
Contact: Carl Hunt, MD    3017675514    carl.hunt@usuhs.edu   
Sponsors and Collaborators
Walter Reed National Military Medical Center
National Institutes of Health (NIH)
DSM Nutritional Products, Inc.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Investigators
Layout table for investigator information
Principal Investigator: Peter F Knickerbocker, DO Walter Reed National Miltary Medical Center
Study Director: Kim Hee-Yong, PhD NIH/ NIAAA
Study Chair: Carl Hunt, MD Uniformed Services University of the Health Sciences

Publications:

Layout table for additonal information
Responsible Party: Walter Reed National Military Medical Center
ClinicalTrials.gov Identifier: NCT04069195     History of Changes
Other Study ID Numbers: WRNMMC-2018-0126
First Posted: August 26, 2019    Key Record Dates
Last Update Posted: August 26, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: All study data will be coded and master key will only be available to study personnel at Walter Reed National Military Medical Center. No decoded study data will be provided to the NIH/NIAAA

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Walter Reed National Military Medical Center:
Inflammation
DHA
Pregnancy
preterm
overweight
Additional relevant MeSH terms:
Layout table for MeSH terms
Inflammation
Pathologic Processes